Pyrsopoulos N, et al. - The safety and efficacy of ledipasvir/sofosbuvir (LED/SOF) with or without ribavirin (RBV) in orthotopic liver transplantation (OLT) patients with recurrent hepatitis C (RHC) was evaluated in this investigation. This study was conducted on seventy-one patients. For this analysis, subjects at least 3 months post-OLT and with documented RHC were treated with LED/SOF with or without RBV for either 12 or 24 weeks. During treatment, no patient required an adjustment in immunosuppression and no episodes of rejection were documented. In treating OLT recipients with RHC, the combination of LED/SOF with RBV for 12 weeks or LED/SOF for 24 weeks was very powerful and harmless.